A data-based assessment of alternative strategies for identification of potential human cancer hazards

Toxicologic Pathology

Volumn 37, Issue 6, 2009, Pages 714-732

  Boobis, R Alan ^a   Cohen, M Samuel ^b   Doerrer, G Nancy ^c   Galloway, M Sheila ^d   Haley, J Patrick ^e   Hard, C Gordon ^f   Hess, G Frederick ^d   Macdonald, S James ^g   Thibault, Stéphane ^h   Wolf, C Douglas ^h   Wright, Jayne ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Experimental Station   (United States)

^f BASF Corporation ^*

^g PFIZER INC   (United States)

^h U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Carcinogenesis; Carcinogenicity testing; Dna reactivity; Immunosuppression; Kidney carcinogenesis; Liver carcinogenesis; Lung carcinogenesis; Mode of action; Nongenotoxic carcinogens

Indexed keywords

2 METHYLIMIDAZOLE; 2 NITROTOLUENE; ANTHRAQUINONE; BENZOPHENONE; CARCINOGEN; DECALIN; FUMONISIN B1; GALLIUM ARSENIDE; INDIUM PHOSPHIDE; METHYLEUGENOL; OXYMETHOLONE; PENTOSAN POLYSULFATE; PROPYLENE GLYCOL MONO TERT BUTYLETHER; RIDDELLINE; TRIETHANOLAMINE; UNCLASSIFIED DRUG; URETHAN; VANADIUM PENTOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER RISK; CARCINOGEN TESTING; CARCINOGENIC ACTIVITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENOTOXICITY; HAZARD ASSESSMENT; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REFERENCE DATABASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RODENT; TUMOR MODEL;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNE SYSTEM PROCESSES; MALE; MICE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RISK ASSESSMENT;

RODENTIA;

EID: 70649088692     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309343779     Document Type: Article

References (92)

1. Alden, C. L., Smith, P. F., Piper, C. E., and Brej, L. (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol Pathol 24, 722-25.
2. Allen, D. G., Pearse, G., Haseman, J. K., and Maronpot, R. R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Tox Pathol 32, 393-401.
3. Ames, B. N. (1973). Carcinogens are mutagens: Their detection and classification. Environ Health Perspect 6, 115-18.
4. Ames, B. N., Durston, W. E., Yamasaki, E., and Lee, F. D. (1973). Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70, 2281-85.
5. Ames, B. N., and Gold, L. S. (1997). The causes and prevention of cancer: gaining perspective. Environ Health Perspect 105 (Suppl. 4), 865-73.
6. Aranda, M., Perez-Alzola, L. P., Ellahuene, M. F., and Sepulveda, C. (2000). Assessment of in vitro mutagenicity in Salmonella and in vivo genotoxicity in mice of the mycotoxin fumonisin B1. Mutagenesis 15, 469-71.
7. Armitage, P., and Doll, R. (1954). The age distribution of cancer and a multistage theory of carcinogenesis. Int J Epidemiol 33, 1174-79.
8. Ashby, J., and Purchase, I. F. H. (1993). Will all chemicals be carcinogenic to rodents when adequately evaluated? Mutagenesis 8, 489-93.
9. Bean, C. L., Armstrong, M. J., and Galloway, S. M. (1992). Effect of sampling time on chromosome aberration yield for 7 chemicals in Chinese hamster ovary cells. Mutat Res 265, 31-44.
10. Berenblum, I., ed. (1969). Carcinogenicity testing. A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC, vol 2. Geneva, Switzerland: International Union Against Cancer.
11. Berenblum, I., and Shubik, P. (1947). A quantitative approach to the study of the stages of chemical carcinogenesis in the mouse skin. Br J Cancer Res 1, 383-91.
12. Berenblum, I., and Shubik, P. (1949). The persistence of latent tumour cells induced in the mouse's skin by a single application of 9, 10-dimethyl-1, 2-benzanthracene. Br J Cancer Res 3, 384-86.
13. Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M. E., Vickers, C., Willcocks, D., and Farland, W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36, 781-92.
14. Bucci, T. J., Howard, P. C., Tolleson, W. H., Laborde, J. B., and Hansen, D. K. (1998). Renal effects of fumonisin mycotoxins in animals. Toxicol Pathol 26, 160-64.
15. Butterworth, B. E., and Bogdanffy, M. S. (1999). A comprehensive approach to the integration of toxicity and cancer risk assessment. Regul Toxicol Pharmacol 29, 23-36.
16. Butterworth, B. E., Mathre, O. B., and Ballinger, K. (2001). The preparation of anthraquinone used in the National Toxicology Program cancer bioassay was contaminated with the mutagen 9-aminoanthracene. Mutagenesis 16, 169-77.
17. Cohen, S. M. (1998a). Cell proliferation and carcinogenesis. Drug Metab Rev 30, 339-57.
18. Cohen, S. M. (1998b). Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. Int J Toxicol 17, 129-42.
19. Cohen, S. M. (2004). Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci 80, 225-29.
20. Cohen, S. M., and Ellwein, L. B. (1990). Cell proliferation in carcinogenesis. Science 249, 1007-11.
21. Cohen, S. M., and Ellwein, L. B. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51, 6493-505.
22. Cohen, S. M., Klaunig, J., Meek, M. E., Hill, R. N., Pastoor, T., Lehman-McKeeman, L., Bucher, J., Longfellow, D. G., Seed, J., Dellarco, V., and Fenner-Crisp, P. (2004). Evaluating the human relevance of chemicallyinduced animal tumors. Toxicol Sci 78, 181-86.
23. Doi, A. M., Irwin, R. D., and Bucher, J. R. (2005). Influence of functional group substitutions on the carcinogenicity of anthraquinone in rats and mice: Analysis of long-term bioassays by the National Cancer Institute and the National Toxicology Program. J Toxicol Environ Health B Crit Rev 8, 109-26.
24. 1 as an example. Toxicol Sci 61, 6-17.
25. Druckrey, H. (1967). Quantitative aspects in chemical carcinogenesis. In Potential carcinogenic hazards from drugs, UICC Monograph Series vol. 7, ed. ed. R. Truhaut, 60-78. New York: Springer-Verlag.
26. Dybing, E., and Sanner, T. (1999). Species differences in chemical carcinogenesis of the thyroid gland, kidney and urinary bladder. In Species differences in thyroid, kidney and urinary bladder carcinogenesis, no. 147, ed. C. C. Capen, E. Dybing, J. M. Rice, and J. D. Wilbourn, 15-32. Lyon, France: IARC Scientific Publications.
27. Elcombe, C. R., Odum, J., Foster, J. R., Stone, S., Hasmall, S., Soames, A. R., Kimber, I., and Ashby, J. (2002). Prediction of rodent nongenotoxic carcinogenesis: Evaluation of biochemical and tissue changes in rodents following exposure to 9 nongenotoxic NTP carcinogens. Environ Health Perspect 110, 363-75.
28. Ennever, F. K., and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul Toxicol Pharmacol 38, 52-57.
29. Epstein, S. S. (1979). The politics of cancer. New York: Anchor.
30. Foulds, L. (1954). The experimental study of tumor progression: A review. Cancer Res 14, 327-39.
31. Frijters, R., Verhoeven, S., Alkema, W., van Schaik, R., and Polman, J. (2007). Literature-based compound profiling: Application to toxicogenomics. Pharmacogenomics 8, 1521-34.
32. Fung, V. A., Barrett, J. C., and Huff, J. E. (1995). The carcinogenesis bioassay in perspective: application in identifying human cancer hazard. Environ Health Perspect 103, 680-83.
33. Galloway, S. M., Aardema, M. J., Ishidate, M., Ivett, J. L., Kirkland, D. J., Morita, T., Mosesso, P., and Sofuni, T. (1994). Report from the working group on in vitro tests for chromosomal aberrations. Mutat Res 312, 241-61.
34. Gaylor, D. W. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol 41, 128-33.
35. Goodman, J. I., and Watson, R. E. (2002). Altered DNA methylation: A secondary mechanism involved in carcinogenesis. Annu Rev Pharmacol Toxicol 42, 501-25.
36. Greenfield, R. E., Ellwein, L. B., and Cohen, S. M. (1984). A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. Carcinogenesis 5, 437-45.
37. Grulich, A. E., Van Leeuwen, M. T., Falster, M. O., and Vajdic, C. M. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370, 59-67.
38. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
39. Hard, G. C., Howard, P. C., Kovatch, R. M., and Bucci, T. J. (2001). Rat kidney pathology induced by chronic exposure to Fumonisin B1 includes rare variants of renal tubule tumor. Environ Pathol 29, 379-86.
40. Hard, G. C., Johnson, K. J., and Cohen, S. M. (2009). A comparison of rat chronic progressive nephropathy (CPN) with human renal disease-Implications for human risk assessment. Crit Rev Toxicol 39, 332-46.
41. Haseman, J. K. (1984). Statistical issues in the design, analysis, and interpretation of animal carcinogenicity studies. Environ Health Perspect 58, 385-92.
42. Holsapple, M. P., Pitot, H. C., Cohen, S. M., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89, 51-56.
43. Hoshi, M., Morimura, K., Wanibuchi, H., Wei, M., Okochi, E., Ushijima, T., Takaoka, K., and Fukushima, S. (2004). No-observed effect levels for carcinogenicity and for in vivo mutagenicity of a genotoxic carcinogen. Toxicol Sci 81, 273-79.
44. Howard, P., Warbritton, A., Voss, K., Lorentzen, R., Thurman, D., Kovach, R., and Bucci, T. (2001). Compensatory regeneration as a mechanism for renal tubule carcinogenesis of fumonisin B1 in the F344/N/NCTR BR rat. Environ Health Perspect Suppl 109 (Suppl. 2), 309-14.
45. International Conference on Harmonisation. (2005). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. Immunotoxicity Studies for Human Pharmaceuticals. S8. http://www.ich.org/LOB/ media/MEDIA1706.pdf
46. Kirkland, D. J., Aardema, M., Banduhn, N., Carmichael, P., Fautz, R., Meunier, J. R., and Pfuhler, S. (2007). In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. Mutagenesis 22, 61-75.
47. Kirkland, D., Aardema, M., Henderson, L., and Müller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res 584, 1-256.
48. (Erratum in Mutat Res 588, 70).
49. Klein, G., and Klein, E. (1984). Commentary: Oncogene activation and tumor suppression. Carcinogenesis 5, 3362-64.
50. Knudson, A. G. (1971). Mutation and cancer: Statistical study of retinoblastomas. Proc Nat Acad Sci 68, 820-23.
51. Lerda, D., Biaggi-Bistoni, M., Peralta, N., Ychari, S., Vazquez, M., and Bosio, G. (2005). Fumonisins in foods from Cordoba (Argentina) : Presence and genotoxicity. Food Chem Toxicol 43, 691-98.
52. Lock, E. A., and Hard, G. C. (2004). Chemically induced renal tubule tumors in the laboratory rat and mouse: Review of the NCI/NTP database and categorization of renal carcinogens on mechanistic information. Crit Rev Toxicol 34, 211-99.
53. MacDonald, J., French, J. E., Gerson, R. J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F. D., Storer, R., and van der Laan, J. W., ILSI HESI Alternative to Carcinogenicity Testing Committee. (2004). The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. Toxicol Sci 77, 188-94.
54. MacDonald, J. S., and Scribner, H. E. (1999). The maximum tolerated dose and secondary mechanisms of carcinogenesis. In Carcinogenicity, ed. K. T. Kitchin, chap. 3, 125-44. New York: Marcel-Dekker.
55. Matthews, E. J., Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. (2006). An analysis of genetic toxicity, reproductive and developmental toxicity and carcinogenicity data, II. Identification of genotoxicants, reprotoxicants and carcinogens using in silico methods. Regul Toxicol Pharmacol 44, 97-110.
56. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33, 591-653. (Pubitemid 38040084)
57. Moolgavkar, S. H., and Knudson, A. G., Jr. (1981). Mutation and cancer: A model for human carcinogenesis. J Natl Cancer Inst 66, 1037-45.
58. National Toxicology Program. (1999). Toxicology and carcinogenesis studies of Oxymetholone (CAS No. 434-07-1) in F344 rats and toxicology studies of oxymetholone in B6C3F1 mice (Gavage Studies). NTP Technical Report Series 485, NIEHS, Research Triangle Park, NC. http://ntp. niehs. nih.gov/ntp/htdocs/ LT-rpts/tr485.pdf
59. 1 mice (Inhalation Studies). NTP Technical Report Series 492, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr492. pdf
60. National Toxicology Program. (2000b). Toxicology and carcinogenesis studies of Methyleugenol (CAS NO. 93-15-2) in F344/N rats and B6C3F1 mice (Gavage Studies). NTP Technical Report Series 491, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr491.pdf
61. 1 mice (Feed Studies). NTP Technical Report Series 496, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr496. pdf
62. 1 mice (Inhalation Studies). NTP Technical Report Series 499, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr499. pdf
63. 1 mice (Feed Studies). NTP Technical Report Series 504, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr504.pdf
64. National Toxicology Program. (2002b). Toxicology and carcinogenesis studies of Vanadium Pentoxide (CAS No. 1314-62-1) in F344/N rats and B6C3F1 mice (Inhalation). NTP Technical Report Series 507, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr507.pdf
65. 1 mice (Gavage Studies). NTP Technical Report Series 508, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr508.pdf
66. 1 mice (Gavage Studies). NTP Technical Report Series 512, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr512. pdf
67. 1 mice and a toxicology study of Propylene Glycol Mono-t-Butyl Ether in male NBR rats (Inhalation Studies). NTP Technical Report Series 515, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/ htdocs/LT-rpts/tr515.pdf
68. 1 mice (Dermal Studies). NTP Technical Report Series 518, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/ntp/htdocs/LT-rpts/tr518.pdf
69. 1 mice (Feed Studies). NTP Technical Report Series 516, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/files/516final-web.pdf
70. 1 mice (Drinking Water Studies). NTP Technical Report Series 510, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/files/tr510-full.pdf
71. 1 mice (Feed Studies). NTP Technical Report Series 494, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/files/TR494web1.pdf
72. 1 mice and a toxicology study of Decalin in male NBR rats (Inhalation Studies). NTP Technical Report Series 513, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/files/TR-513.pdf
73. 1 mice (Feed Studies). NTP Technical Report Series 533, NIEHS, Research Triangle Park, NC. http://ntp. niehs.nih.gov/files/533-Web.pdf
74. Norred, W. P., Plattner, R. D., Vesonder, R. F., Bacon, C. W., and Voss, K. A. (1992). Effects of selected secondary metabolites on Fusarium moniliforme on unscheduled synthesis of DNA by rat primary hepatocytes. Food Chem Toxicol 30, 233-37.
75. Norton, N., ed. (1981). Assessment of technologies for determining cancer risks from the environment. Washington, DC: Office of Technology Assessment.
76. Nyska, A., Nold, J. B., Johnson, J. D., and Abdo, K. (2002). Lysosomal-storage disorder induced by Elmiron following 90-days gavage administration in rats and mice. Toxicol Pathol 30, 178-87.
77. Oberdörster, G. (1995). Lung particle overload: Implications for occupational exposures to particles. Regul Toxicol Pharmacol 21, 123-35.
78. Rhomberg, L. R., Baetcke, K., Blancato, J., Bus, J., Cohen, S., Conolly, R., Dixit, R., Doe, J., Ekelman, K., Fenner-Crisp, P., Harvey, P., Hattis, D., Jacobs, A., Jacobson-Kram, D., Lewandowski, T., Liteplo, R., Pelkonen, O., Rice, J., Somers, D., Turturro, A., West, W., and Olin, S. (2007). Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection. Crit Rev Toxicol 37, 729-837.
79. Roe, F. J. (1989). What is wrong with the way we test chemicals for carcinogenic activity? In Advances in applied toxicology, ed. A. D. Dayan and A. J. Paine, chap. 2, 2-17. London: Taylor & Francis.
80. Serraino, D., Piselli, P., Busnach, G., Burra, P., Citterio, F., Arbustini, E., Baccarani, U., De Juli, E., Pozzetto, U., Bellelli, S., Polesel, J., Pradier, C., Dal Maso, L., Angeletti, C., Carrieri, M. P., Rezza, G., and Franceschi, S. (2007). Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 43, 2117-23.
81. Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., Mangelsdorf. I., Meek, E., Rice, J. M., and Younes, M., International Programme on Chemical Safety. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol 34, 146-52.
82. Swenberg, J. A., Ham, A., Koc, H., Morinello, E., Ranasinghe, A., Tretyakova, N., Upton, P. B., and Wu, K. (2002). DNA adducts: Effects of low exposure to ethylene oxide, vinyl chloride and butadiene. Mutat Res 464, 77-86.
83. Tweats, D. J., Blakey, D., Heflich, R. H., Jacobs, A., Jacobsen, S. D., Morita, T., Nohmi, T., O'Donovan, M. R., Sasaki, Y. F., Sofuni, T., and Tice, R., IWGT Working Group. (2007). Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests. I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutat Res 627, 78-91.
84. U. S. Environmental Protection Agency. (2002). Hepatocellular hypertrophy, HED Guidance Document #G2002.01. Washington, DC: US EPA HED Toxicology Science Advisory Council.
85. U. S. Environmental Protection Agency. (2005). Guidelines for carcinogen risk assessment, EPA/630/P-03/001F. Washington, DC: National Center for Environmental Assessment.
86. U. S. Food and Drug Administration. (1996). Guideline for industry. Specific aspects of regulatory genotoxicity tests for pharmaceuticals. ICH S2A. http://www.fda.gov/cder/guidance/ichs2a.pdf
87. Van Oosterhout, J. P., van der Laan, J. W., De Waal, E. J., Olejniczak, K., Hilgenfeld, M., Schmidt, V., and Bass, R. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 25, 6-17.
88. Voss, K. A., Chamberlain, W. J., Bacon, C. W., Herbert, R. A., Walters, D. B., and Norred, W. P. (1995). Subchronic feeding study of the mycotoxin fumonisin B1 in B6C3F1 mice and Fischer 344 rats. Fund Appl Toxicol 24, 102-10.
89. Weisburger, E. K. (1981). Techniques for carcinogenicity studies. Cancer Res 41, 3690-94.
90. Weisburger, E. K. (1983). History of the bioassay program of the National Cancer Institute. Prog Exp Tumor Res 26, 187-201.
91. Weisburger, J. H., and Williams, G. M. (1981). Carcinogen testing: Current problems and new approaches. Science 214, 401-7.
92. Williams, G. M., Iatropoulos, M. J., and Jeffrey, A. M. (2004). Thresholds for the effects of 2-acetylaminofluorene in rat liver. Toxicol Pathol 32, 85-91.